Crossmark

Stakeholders’ perspectives on the contemporary landscape of pharmaceutical market competition in Malaysia’s public sector: exploring the key influences of economic, regulatory, and public procurement policies and practices

Crossref DOI link: https://doi.org/10.1186/s12913-026-15367-4

Published Online: 2026-08-20

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Mohd Kasim, Farahwahida

Hatah, Ernieda

Osman, Lokhman Hakim

Mhd Ali, Adliah

Babar, Zaheer-Ud-Din
Funding

Funding for this research was provided by:

Ministry of Higher Education of Malaysia (FRGS/1/2022/SS02/UKM/02/1)
License Information

Text and Data Mining valid from 2026-08-20

Accepted Manuscript valid from 2026-08-20
More Information

Article History

Received: 10 December 2024

Accepted: 11 August 2026

First Online: 20 August 2026

Declarations

Ethics approval and consent to participate: The ethical approval for the study protocol was obtained from the Medical Research and Ethics Committee, Ministry of Health Malaysia (NMMR ID: 23-02599-BSA (IIR)) and from the Universiti Kebangsaan Malaysia Research Ethics Committee (UKM PPI/111/8/JEP-2023-894). The study was adhered to the Declaration of Helsinki. Participants in this study were provided with a participant information sheet and consent form, which they reviewed and agreed to before the interview began.

Consent for publication: Not applicable.

Competing interests: The authors declare no competing interests.

Document is current

Any future updates will be listed below